Vise Technologies Inc. Takes $814,000 Position in Corcept Therapeutics Incorporated $CORT

Vise Technologies Inc. purchased a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 9,366 shares of the biotechnology company’s stock, valued at approximately $814,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lisanti Capital Growth LLC acquired a new stake in Corcept Therapeutics during the second quarter valued at $7,965,000. NewEdge Wealth LLC acquired a new position in Corcept Therapeutics in the 2nd quarter worth about $3,034,000. Citizens Financial Group Inc. RI acquired a new position in Corcept Therapeutics in the 2nd quarter worth about $348,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Corcept Therapeutics during the 2nd quarter worth about $307,000. Finally, BlackRock Inc. purchased a new stake in shares of Corcept Therapeutics during the 2nd quarter worth about $1,080,964,000. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CORT shares. Canaccord Genuity Group boosted their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Weiss Ratings upgraded shares of Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday. HC Wainwright boosted their target price on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a research report on Monday, July 27th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Corcept Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $138.17.

Insider Activity

In other Corcept Therapeutics news, Director James N. Wilson sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $111.43, for a total value of $1,114,300.00. Following the sale, the director owned 1,074,543 shares of the company’s stock, valued at $119,736,326.49. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David L. Mahoney sold 103,606 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $118.25, for a total value of $12,251,409.50. Following the completion of the transaction, the director directly owned 1,133,539 shares in the company, valued at approximately $134,040,986.75. This represents a 8.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 520,146 shares of company stock worth $48,903,764 over the last 90 days. Company insiders own 20.70% of the company’s stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks sharply raised long-term earnings forecasts. The firm increased its FY2026 EPS estimate to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also raised, including Q1 2027 to $0.11 from a projected loss of $0.17 and Q2 2028 to $1.17 from $0.69. These revisions signal expectations for accelerating profitability.
• Positive Sentiment: Recent operating results provide support for the bullish outlook. Corcept’s latest reported quarter produced $0.36 in EPS versus the $0.02 consensus estimate, while revenue of $256.15 million exceeded expectations of $221.15 million and grew 31.7% year over year.
• Positive Sentiment: Analyst sentiment and price targets remain constructive. Recent coverage includes Buy or Overweight ratings and price targets ranging from $150 to $165, while the reported consensus rating is “Moderate Buy” with a $138.17 target. An investment analysis also argued that the launch of Lifyorli and continued Korlym growth could drive revenue growth, margin expansion and further EPS upside. Like The Knicks, Corcept Rebounded And Is Crushing It
• Neutral Sentiment: Zacks maintained a “Hold” rating. The improved earnings estimates are encouraging, but the unchanged rating suggests the analyst views the stock’s substantial rally and high valuation as partly reflected in the price.
• Negative Sentiment: Director David Mahoney sold 103,606 shares for approximately $12.25 million. The transaction reduced his ownership by 8.37%, although he still retained more than 1.13 million shares. The sale could create short-term sentiment pressure, but it does not necessarily indicate a change in the company’s fundamentals. Insider Selling: Corcept Therapeutics Director Sells Stock

Corcept Therapeutics Price Performance

Shares of CORT opened at $122.25 on Monday. The company has a market capitalization of $13.22 billion, a PE ratio of 291.08 and a beta of 0.45. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $123.44. The company’s fifty day moving average price is $97.39 and its 200 day moving average price is $64.76.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34. The company had revenue of $256.15 million for the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm’s revenue was up 31.7% compared to the same quarter last year. During the same period last year, the business posted $0.29 earnings per share. Analysts anticipate that Corcept Therapeutics Incorporated will post 1.77 earnings per share for the current year.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.